Artiva Overview
- Year Founded
-
2019
- Status
-
Public
- Employees
-
89
- Stock Symbol
-
ARTV
- Share Price
-
$2.24
- (As of Thursday Closing)
Artiva General Information
Description
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
Contact Information
Website
www.artivabio.comCorporate Office
- 5505 Morehouse Drive
- Suite 100
- San Diego, CA 92121
- United States
Corporate Office
- 5505 Morehouse Drive
- Suite 100
- San Diego, CA 92121
- United States
Artiva Stock Performance
As of 17-Apr-2025, Artiva’s stock price is $2.24. Its current market cap is $54.6M with 24.4M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.24 | $2.30 | $1.78 - $17.31 | $54.6M | 24.4M | 279K | -$5.81 |
Artiva Financials Summary
As of 31-Dec-2024, Artiva has a trailing 12-month revenue of $251K.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 113,173 | 113,173 | ||
| Revenue | 251 | 251 | 33,492 | 4,931 |
| EBITDA | (61,411) | (61,411) | (27,893) | (58,471) |
| Net Income | (58,493) | (58,493) | (27,696) | (58,388) |
| Total Assets | 209,581 | 209,581 | 105,114 | 133,054 |
| Total Debt | 14,354 | 14,354 | 16,912 | 19,448 |
Artiva Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Artiva Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Artiva Comparisons
Industry
Financing
Details
Artiva Competitors (7)
One of Artiva’s 7 competitors is Nkarta Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Nkarta Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Compass Therapeutics | Formerly VC-backed | Boston, MA | ||||
| Poseida Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Fate Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Catamaran Bio | Venture Capital-Backed | Boston, MA |
Artiva Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Artiva Patents
Artiva Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023325154-A1 | Methods of administering natural killer cells comprising an anti-human epidermal growth factor receptor 2 (her2) chimeric antigen receptor (car) | Pending | 17-Aug-2022 | ||
| US-D1000680-S1 | Multi loop lamp | Active | 12-Jan-2022 | ||
| CA-3237016-A1 | Treatment of cancer with nk cells and multispecific engagers | Pending | 04-Nov-2021 | ||
| EP-4426350-A2 | Treatment of cancer with nk cells and multispecific engagers | Pending | 04-Nov-2021 | ||
| AU-2022380926-A1 | Treatment of cancer with nk cells and multispecific engagers | Pending | 04-Nov-2021 | A61K40/15 |
Artiva Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Artiva Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Artiva FAQs
-
When was Artiva founded?
Artiva was founded in 2019.
-
Where is Artiva headquartered?
Artiva is headquartered in San Diego, CA.
-
What is the size of Artiva?
Artiva has 89 total employees.
-
What industry is Artiva in?
Artiva’s primary industry is Drug Discovery.
-
Is Artiva a private or public company?
Artiva is a Public company.
-
What is Artiva’s stock symbol?
The ticker symbol for Artiva is ARTV.
-
What is the current stock price of Artiva?
As of 17-Apr-2025 the stock price of Artiva is $2.24.
-
What is the current market cap of Artiva?
The current market capitalization of Artiva is $54.6M.
-
What is Artiva’s current revenue?
The trailing twelve month revenue for Artiva is $251K.
-
Who are Artiva’s competitors?
Nkarta Therapeutics, Compass Therapeutics, Poseida Therapeutics, Fate Therapeutics, and Catamaran Bio are some of the 7 competitors of Artiva.
-
What is Artiva’s annual earnings per share (EPS)?
Artiva’s EPS for 12 months was -$5.81.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
